Plain-English translation of NCT06377696 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , a medication that has been used for many years to treat other conditions, can help protect memory and thinking skills in people who have received radiation therapy to their brain. Brain radiation can sometimes affect how well people think, remember, and concentrate. Researchers want to see if this medication might help prevent or reduce these changes.
Brain radiation therapy is an important treatment for brain tumors, but it can sometimes harm memory, attention, and other thinking abilities over time. There is no proven way to prevent this problem yet, so doctors are exploring whether this medication might help protect the brain.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two groups for 12 months. One group takes twice a day, while the other group receives standard care without the medication. Both groups will wear a small device that tracks activity and sleep, and both will complete thinking and memory tests several times during the year. After the 12-month treatment period ends, you will have a follow-up visit 30 days later, then check-in visits every 3 months for up to 2 years.
AI-generated summary from trial data · Jul 20, 2026 · Not medical advice
United States